Browsing tag:


Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]

Read More

Darunavir Ethanolate is also known by it’s brand name Prezista, and is used to treat HIV infection. In the class of protease inhibitors, darunavir ethanolate was approved by the FDA in June of 2006. What makes darunavir ethanolate unique is it’s ability to combat drug resistant strains of HIV in affected patients, as well as[…]

Read More

Atazanavir Sulfate, CAS# 229975-97-7, is essential in the management of HIV in affected patients. As an inhibitor of the HIV-1 protease, it is often used in combination with other antiretroviral medications to treat HIV-1 infected patients. LGM Pharma is a provider of the API for research and development. With a trade name Reyataz (Bristol-Myers Squibb),[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service